Aridis Pharmaceuticals to Present at Upcoming Investor Conferences
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced CEO Vu Truong will present at two investor conferences on September 15, 2020. The Cantor Fitzgerald Virtual Global Healthcare Conference is scheduled for 9:20 AM EDT, followed by the H.C. Wainwright 22nd Annual Global Investment Conference at 3:30 PM EDT. A webcast of the Cantor Fitzgerald presentation will be available for 90 days post-event. Aridis focuses on developing innovative anti-infective therapies, leveraging proprietary technologies to combat life-threatening infections.
- None.
- None.
SAN JOSE, Calif., Sept. 4, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced that Vu Truong, Ph.D., Chief Executive Officer, will present at the following investor conferences in September:
- 2020 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 9:20 AM EDT
- H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 3:30 PM EDT
A webcast of the Cantor Fitzgerald presentation will be available at https://investors.aridispharma.com/events. A replay of the webcast will be available on the Company's website for 90 days following the event.
About Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ʎPEX™ and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they do not require genetic engineering or further optimization to achieve full functionality.
The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The Company's pipeline is highlighted below:
Aridis' Pipeline
AR-301 (VAP). AR-301 is a fully human immunoglobulin 1, or IgG1, mAb currently in Phase 3 clinical development targeting gram-positive Staphylococcus aureus (S. aureus) alpha-toxin in VAP patients.
AR-101 (HAP). AR-101 is a fully human immunoglobulin M, or IgM, mAb in Phase 2 clinical development targeting Pseudomonas aeruginosa (P. aeruginosa) liposaccharides serotype O11, which accounts for approximately
AR-501 (cystic fibrosis). AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients. This program is currently in a Phase 1/2a clinical study in healthy volunteers and CF patients.
AR-401 (blood stream infections). AR-401 is a fully human mAb preclinical program aimed at treating infections caused by gram-negative Acinetobacter baumannii.
AR-701 (COVID-19). AR-701 is a fully human mAb cocktail discovered from convalescent COVID-19 patients that are directed at multiple envelope proteins on SARS-CoV-2.
AR-201 (RSV infection). AR-201 is a fully human IgG1 mAb out-licensed preclinical program aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).
For additional information on Aridis Pharmaceuticals, please visit https://aridispharma.com/.
Contact:
Investor Relations
Jason Wong
Blueprint Life Science Group
jwong@bplifescience.com
(415) 375-3340 Ext. 4
View original content to download multimedia:http://www.prnewswire.com/news-releases/aridis-pharmaceuticals-to-present-at-upcoming-investor-conferences-301124588.html
SOURCE Aridis Pharmaceuticals, Inc.
FAQ
When is Aridis Pharmaceuticals presenting at the investor conferences?
What is the focus of Aridis Pharmaceuticals?
Where can I watch the Aridis Pharmaceuticals webcast?
What is the ticker symbol for Aridis Pharmaceuticals?
What technologies does Aridis Pharmaceuticals use?
